United States securities and exchange commission logo





                             November 18, 2020

       Michael Shleifer
       Chief Executive Officer
       Biotech Acquisition Company
       545 West 25th Street, 20th Floor
       New York, NY 10001

                                                        Re: Biotech Acquisition
Company
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted November
13, 2020
                                                            CIK No. 0001825413

       Dear Mr. Shleifer:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted
November 13, 2020

       Management
       Advisors, page 100

   1.                                                   We note the new
disclosure that Messrs. Serra and Tillman will serve as advisors upon
                                                        completion of this
offering. Please revise to describe the roles of the advisors, and also
                                                        disclose whether you
intend to pay any consulting fees or other compensation to the
                                                        advisors. We note
disclosure on page 23 that you may make limited payments to insiders
                                                        for payment of
"customary fees for financial advisory services." Please clarify.
 Michael Shleifer
Biotech Acquisition Company
November 18, 2020
Page 2

        You may contact Yong Kim, Staff Accountant, at (202) 551-3323 or Gus
Rodriguez,
Accounting Branch Chief, at (202) 551-3752 if you have questions regarding
comments on the
financial statements and related matters. Please contact Anuja A. Majmudar,
Attorney-Adviser,
at (202) 551-3844 or, in her absence, Loan Lauren Nguyen, Legal Branch Chief,
at (202) 551-
3642 with any other questions.



                                                          Sincerely,
FirstName LastNameMichael Shleifer
                                                          Division of
Corporation Finance
Comapany NameBiotech Acquisition Company
                                                          Office of Energy &
Transportation
November 18, 2020 Page 2
cc:       Lawrence A. Rosenbloom, Esq.
FirstName LastName